Please fill out the form below and we will gladly respond as soon as possible.
Developing treatments for rare cancers like synovial sarcoma remains one of the biggest challenges in modern medicine—but recent progress shows what’s possible. One major milestone came with the FDA approval of Tecelra, the first engineered T-cell therapy approved for a solid tumor in the U.S., including synovial sarcoma. Why Rare Cancers Face Unique Challenges Synovial […]
A new Phase 1/2 trial in Ewing sarcoma, just profiled in Clinical Trial Vanguard and published in Nature Medicine, delivered the kind of result the synovial sarcoma community should be watching closely. The trial paired trabectedin with low-dose irinotecan to target the EWS::FLI1 fusion, the oncogenic driver of Ewing sarcoma. For more than a decade, […]
A recent BioSpace article highlights a critical challenge in rare disease drug development: many promising therapies are not limited by science, but by financial viability. As Kristen Hege, former SVP at Bristol Myers Squibb, explains:“Right now, as a rule of thumb, if your product isn’t going to bring in a billion dollars a year, it’s […]
Recent industry analyses show that the synovial sarcoma clinical trial pipeline is expanding, with more than 15 companies developing over 20 investigational therapies aimed at improving treatment options for this rare cancer. Although synovial sarcoma remains difficult to treat, the growing number of clinical trials reflects increasing research investment and scientific focus on this disease. […]
Recent industry analyses suggest the synovial sarcoma treatment market is expected to grow steadily, with projections estimating a compound annual growth rate (CAGR) of approximately 7.9% from 2026 to 2033. While market reports focus on financial trends and market size, they also reflect increasing investment in rare cancer research, drug development pipelines, and emerging therapies. […]
A recent market analysis estimates that the global synovial sarcoma treatment market was valued at approximately $832 million in 2023 and is projected to reach $1.6 billion by 2031. While market reports focus on financial projections, they often reflect broader trends in research, drug development, and clinical trial activity. For the synovial sarcoma community, this […]
Zelluna, a Norway-based biotechnology company, has announced the submission of a Clinical Trial Application (CTA) in the United Kingdom for ZI-MA4-1 (ZIMA-101), a first-in-human cell therapy study that will include patients with synovial sarcoma. While this trial is still in its earliest phase, it represents a notable scientific development for the synovial sarcoma community. What […]
The Synovial Sarcoma Foundation is proud to announce a significant milestone in pediatric cancer research: Dr. Rachel Hurly, a dedicated pediatric oncology fellow from the Children’s Hospital of Philadelphia (CHOP), has been honored with the prestigious American Society of Clinical Oncology (ASCO) Young Investigator Award. Dr. Hurly conducts her research under the mentorship of Dr. Ted Laetsch at the Haldor Laboratory at the University of Pennsylvania, with support from the Synovial Sarcoma Fund.
Thanks to the generosity of donors and supporters, the Fund has now raised over $2 million, accelerating research initiatives at CHOP and Penn Medicine. These funds are driving critical advancements in patient care, clinical trials, and the development of future treatment strategies. This milestone represents a major step forward in expanding Synovial Sarcoma research, allowing […]